Johnson & Johnson | 10-Q: Q1 2025 Earnings Report

Johnson & Johnson reported Q1 2025 revenue of $21.9 billion, up 2.4% year-over-year, with operational growth of 4.2% offset by a 1.8% negative currency impact. Innovative Medicine sales rose 2.3% to $13.9 billion, while MedTech revenue increased 2.5% to $8.0 billion. Net earnings surged to $11.0 billion, boosted by the reversal of approximately $7.0 billion from previously accrued talc reserves.The Innovative Medicine segment saw strong performance in Oncology, up 20.4% operationally, driven by DARZALEX and CARVYKTI growth. However, Immunology sales declined 10.9% operationally due to STELARA biosimilar competition. MedTech growth was led by the Cardiovascular franchise, up 17.7% operationally, including contributions from the acquired Shockwave business.Looking ahead, the company completed the $14.6 billion acquisition of Intra-Cellular Therapies in April 2025, funded through cash and recent debt issuance. The company maintains strong liquidity with $38.8 billion in cash and marketable securities, while continuing to invest in R&D and returning value to shareholders through a 4.8% dividend increase to $1.30 per share.

Johnson & Johnson reported Q1 2025 revenue of $21.9 billion, up 2.4% year-over-year, with operational growth of 4.2% offset by a 1.8% negative currency impact. Innovative Medicine sales rose 2.3% to $13.9 billion, while MedTech revenue increased 2.5% to $8.0 billion. Net earnings surged to $11.0 billion, boosted by the reversal of approximately $7.0 billion from previously accrued talc reserves.The Innovative Medicine segment saw strong performance in Oncology, up 20.4% operationally, driven by DARZALEX and CARVYKTI growth. However, Immunology sales declined 10.9% operationally due to STELARA biosimilar competition. MedTech growth was led by the Cardiovascular franchise, up 17.7% operationally, including contributions from the acquired Shockwave business.Looking ahead, the company completed the $14.6 billion acquisition of Intra-Cellular Therapies in April 2025, funded through cash and recent debt issuance. The company maintains strong liquidity with $38.8 billion in cash and marketable securities, while continuing to invest in R&D and returning value to shareholders through a 4.8% dividend increase to $1.30 per share.